Medeze Group Public Company Limited (SET: MEDEZE) has informed the Stock Exchange of Thailand regarding recent reports published through online media and others, which may have raised concerns among shareholders and investors regarding the operational activities of the company.
The reports originated from an academic seminar conducted as part of the “รายการชวนหมอรู้ครั้งที่ 5” which featured a discourse on the application of stem cells for medical purposes. This seminar occurred on October 31, 2024. It was a collaborative effort involving the Ministry of Public Health, the Medical Council, the Department of Health Service Support, and the Food and Drug Administration.
During the seminar, the Medical Council expressed its concerns and outlined its objective of promoting the appropriate and widespread application of stem cells within the healthcare sector.
Medeze Group has clarified its role and services regarding stem cell banking. The company provides specialized stem cell banking services and adheres to international standards for stem cell storage established by the Association for Advancement of Blood and Biotherapies (AABB) in the United States.
AABB is a globally recognized organization that sets strict operational standards in stem cell banking, and Medeze Group practices comply with the international quality control standards mandated by the U.S. Food and Drug Administration (USFDA).
It is important to note that Medeze Group does not function as a healthcare provider. As part of the company’s stem cell banking services, they perform assessments of cell quality, isolation, and culture following medical and Thailand’s stem cell banking standards.
Medeze Group supports using stem cells to treat diseases as outlined by the Medical Council, The Thai Society of Hematology, and other relevant governmental authorities to ensure adherence to legal regulations.
The utilization of stem cells for medical applications is strictly restricted to individuals who possess the stem cells stored with the company. All medical treatments involving these stem cells are carried out under the supervision of licensed physicians and authorized healthcare institutions, fully complying with all relevant laws, regulations, medical standards, and directives issued by the Ministry of Public Health.
Medeze Group significantly emphasizes responsible advertising and public relations about the company operations. Medeze has established standards for advertising and publicizing its services, implementing a policy to control promotional activities. This policy is based on the guidelines outlined in healthcare facility regulations.
Medeze Group has established a risk management team to oversee advertising and public relations. This team works closely with executives and employees, regularly reporting to the Board of Directors to ensure that all promotional activities comply with current laws and are prepared to meet any future legal requirements that may be enacted.
Medeze Group is seeking to assure shareholders, investors, and all stakeholders of its unwavering commitment to full compliance with all applicable laws, regulations, directives, and guidelines established by relevant authorities, including the Ministry of Public Health, the Medical Council, and the Food and Drug Administration (FDA).
The Company adheres to good governance, transparency, and accountability principles, and is committed to providing stem cell banking services and developing new innovations that support the lawful application of stem cells in healthcare.
